Library / Metabolic / Adipotide
Prohibitin-targeting peptide · FTPP
Adipotide
Preclinical High caution
ClassExperimental targeted pro-apoptotic peptide
Typical routes in papersResearch injections in animals / early work
Half-life contextExperimental
EvidenceAnimal fat-ablation models; human path not established as a drug
What it is
Adipotide was designed to bind prohibitin on white-fat blood vessels and shut those vessels down so fat pads shrink.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Animal papers showed striking fat loss. That is why the name will not die on forums.
- Killing blood vessels in fat is also a kidney-and-safety problem. Early human exploration was not a happy consumer story.
- Treat this as a cautionary monograph, not a stack idea.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Targeting peptide + apoptotic motif against prohibitin-expressing endothelium in white adipose vasculature.
Possible side effects / caveats
Renal toxicity signals are the headline risk. Not a cosmetic fat peptide.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Preclinical | mg/kg animal scales | Do not convert | No human community dose belongs here |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.